Drug Trial Radar · NCT04020341
A Study to Evaluate Efficacy and Safety of Gepotidacin in the Treatment of Uncomplicated Urinary Tract Infection (UTI)
Last checked: Nov 19, 2026Latest source record: Jun 22, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,531
Actual
Start
Oct 17, 2019
Primary completion
Nov 30, 2022
Study completion Nov 30, 2022
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- First posted
- Jul 16, 2019
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study will be conducted to evaluate the therapeutic response (combined per participant microbiological and clinical response) of oral gepotidacin compared to oral nitrofurantoin for treatment of uncomplicated UTI (acute cystitis) in adolescent and adult female participants.
Conditions
- Urinary Tract Infections
Interventions
GepotidacinDrug
Gepotidacin will be available as tablets containing 750 mg gepotidacin. Each dose should be taken with water after consumption of food.
Placebo matching nitrofurantoinDrug
Placebo matching nitrofurantoin will be available as over-encapsulated unit-dose capsules. Each dose should be taken with water after consumption of food.
NitrofurantoinDrug
Nitrofurantoin will be available as over-encapsulated capsules containing 25 mg nitrofurantoin macrocrystals and 75 mg nitrofurantoin. Each dose should be taken with water after consumption of food.
Placebo matching gepotidacinDrug
Placebo matching gepotidacin will be available as unit-dose gepotidacin placebo-to-match tablet. Each dose should be taken with water after consumption of food.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Therapeutic Response (TR) (Combined Per Participant Clinical and Microbiological Response) at the Test-of-Cure (TOC) Visit - Micro-ITT NTF-S (IA Set)Time frame: TOC visit (Days 9 to 16)
- Number of Participants With Therapeutic Response (TR) (Combined Per Participant Clinical and Microbiological Response) at the Test-of-Cure (TOC) Visit - Micro-ITT NTF-S PopulationTime frame: TOC visit (Days 9 to 16)
Locations
103 sites in 12 countries. Site status is shown where the registry gives one.
GSK Investigational Site
Birmingham, Alabama
GSK Investigational Site
Phoenix, Arizona
GSK Investigational Site
Tucson, Arizona
GSK Investigational Site
Beverly Hills, California
GSK Investigational Site
Chula Vista, California
GSK Investigational Site
La Mesa, California
GSK Investigational Site
Lomita, California
GSK Investigational Site
Long Beach, California
GSK Investigational Site
Northridge, California
GSK Investigational Site
Northridge, California
GSK Investigational Site
Palm Springs, California
GSK Investigational Site
San Diego, California
GSK Investigational Site
DeLand, Florida
GSK Investigational Site
Hialeah, Florida
GSK Investigational Site
Miami, Florida
GSK Investigational Site
Miami Springs, Florida
GSK Investigational Site
Orlando, Florida
GSK Investigational Site
Pompano Beach, Florida
GSK Investigational Site
Atlanta, Georgia
GSK Investigational Site
Columbus, Georgia
GSK Investigational Site
Fayetteville, Georgia
GSK Investigational Site
Wichita, Kansas
GSK Investigational Site
New Orleans, Louisiana
GSK Investigational Site
Shreveport, Louisiana
GSK Investigational Site
Watertown, Massachusetts
GSK Investigational Site
Dearborn Heights, Michigan
GSK Investigational Site
Norfolk, Nebraska
GSK Investigational Site
East Brunswick, New Jersey
GSK Investigational Site
Albuquerque, New Mexico
GSK Investigational Site
Endwell, New York
GSK Investigational Site
Fayetteville, North Carolina
GSK Investigational Site
Scottdale, Pennsylvania
GSK Investigational Site
Smithfield, Pennsylvania
GSK Investigational Site
Clarksville, Tennessee
GSK Investigational Site
Memphis, Tennessee
GSK Investigational Site
Arlington, Texas
GSK Investigational Site
Austin, Texas
GSK Investigational Site
Corpus Christi, Texas
GSK Investigational Site
Forney, Texas
GSK Investigational Site
Houston, Texas
Showing 40 of 103 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.